Wegovy
Novo Nordisk Q3 Sales Surge on GLP-1 Meds Amid Manufacturing Queries
Since the FDA gave the green light to Novo Nordisk’s GLP-1 weight-loss medication Wegovy over two years ago, the drug ...
Fake Ozempic products seized in EU and UK, Novo Nordisk warns
As Novo Nordisk grapples with the challenges posed by illicit sales of semaglutide, authorities in the UK and Europe have ...
Novo Nordisk raises its 2023 outlook for sales and profit, driven by strong diabetes and obesity drugs
Novo Nordisk is experiencing a remarkable surge in its fortunes, primarily driven by the widespread popularity of its diabetes medication ...
FDA warns companies selling unauthorized obesity drugs similar to Wegovy and Mounjaro
The soaring demand for new anti-obesity medications has led to a concerning trend, with various online companies attempting to sell ...
Eli Lilly Sues 8 Companies for selling fake Mounjaro versions
The surging demand for GLP-1 diabetes and weight loss medications has led to an inevitable influx of knockoff versions. Earlier ...
Novo Nordisk’s Wegovy boosts heart health, J.P. Morgan predicts $71B GLP-1 market by 2032
The demand for Novo Nordisk’s obesity medications is surging, with production capacity being the primary limiting factor in the short ...
AstraZeneca’s Farxiga confident of its edge over Novo’s Wegovy in heart failure market
Novo Nordisk’s semaglutide and AstraZeneca’s Farxiga assuming the roles of formidable contenders. The arena is no longer confined to blood ...
Novo Nordisk’s Semaglutide Triumphs Again: A Heartfelt Victory in the Battle Against Heart Failure
In a remarkable turn of events, the pharmaceutical landscape witnesses Novo Nordisk’s semaglutide, a true star in its arsenal, claiming ...
Novo Nordisk Turns to Thermo Fisher for Production Aid with Obesity Drug Wegovy Amid Catalent Challenges
Novo Nordisk Struggles to Keep Up with High Demand for Wegovy, Enlists Thermo Fisher to Boost Production Amid soaring demand ...
Novo Nordisk and Eli Lilly Ride Obesity and Diabetes Drugs to the Forefront in Q2 Pharmaceutical Performance
As the COVID-19 pandemic surged and waned, the biopharmaceutical industry witnessed a rollercoaster ride of revenue spikes and troughs. However, ...
Wegovy from Novo Nordisk surges, reaching $1 billion in just one quarter
For Novo overall, there’s “a lot to be proud of” in 2023’s second quarter, the company’s head of North American ...
leading obesity medication Wegovy’s ‘best-case scenario’ Novo Nordisk published cardiac results statistics
Source – Novo Nordisk Novo Nordisk has been capitalizing on the momentum generated by its weight loss drug, Wegovy, which ...
Weighing the benefits and drawbacks of the newest Weight loss medication as well as their financial impact
Weight Loss Medication: Obesity rates in the United States have significantly increased since the 1980s, with a staggering 41.9% of ...
Saxenda is now in low supply as Novo Nordisk issues a supply warning till 2023
Due to a shortage of Novo Nordisk’s popular obesity medicine Wegovy, there has been a surge in demand for their ...
New lawsuits from Novo Nordisk are filed against synthetic versions of Wegovy and Ozempic
Source – FDA The increasing demand for GLP-1 drugs, which can lead to significant weight loss, has resulted in unauthorized ...
Novo Nordisk plans to stop compounded versions of Ozempic and Wegovy with fresh litigation
Source – Fierce Pharma Novo allegedly filed separate lawsuits against health spas, clinics, and pharmacies in Florida, New York, Tennessee, ...
Weight-Loss Medications Market Projected to Reach $60 Billion in 10 Years
According to a Morningstar analyst, frantic demand for pharmaceuticals to treat obesity from Novo Nordisk, Eli Lilly, and other companies ...
